GAL-101 Salt

Phase 2

GAL-101 Salt is one of 6 therapeutic programs targeting Mild to Moderate Alzheimer's Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Mild to Moderate Alzheimer's DiseaseNot yet recruiting

Mild to Moderate Alzheimer's DiseasePhase 2

Not yet recruiting

Competition

Competitive Landscape

6 competitors in Mild to Moderate Alzheimer's Disease

#DrugCompanyPhaseTrials

Choline Alfoscerate

Chong Kun Dang Pharmaceutical

Phase 3

1 2

Sodium Pentaborate

TTabriz University of Medical Sciences

Phase 2

1 3

GAL-101 Salt

GGalimedix Therapeutics Inc

Phase 2

1 4

Neuroepo

IInternational Center for Neurological Restoration, Cuba

Phase 2

1 5

RB-ADSC

RRegeneration Biomedical, Inc.

Phase 1

1 6

RO7126209

Roche

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 2Not yet recruiting

Mild to Moderate Alzheimer's Disease

NCT07789873

Clinical

Trials by Indication[1]

Mild to Moderate Alzheimer's Disease1 trial

A 28-Day Study of GAL-101 in Participants With Mild to Moderate Alzheimer's Disease

Not yet recruiting·GGalimedix Therapeutics Inc·Phase 2·NCT07789873·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for GAL-101 Salt. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for GAL-101 Salt. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Galimedix Therapeutics Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: GGalimedix Therapeutics Inc

GAL-101 Salt

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Mild to Moderate Alzheimer's Disease1 trial

References

Drug Info

Quick Facts

Related News